Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older

Authors:
Publisher website
Google Scholar
Abstract
Background: Consolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used for patients with multiple myeloma (MM). We studied AHCT use and outcomes in patients with MM ≥75 years old.Methods: Patients with MM ≥75 years old receiving AHCT between 2013 and 2017 in the United States were identified using the Center for International Blood and Marrow Transplant Research database. Relapse and/or progression (REL), progression‐free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models. Covariates used were age, sex, Karnofsky performance score (KPS), HCT‐comorbidity index (HCT‐CI), International Staging System and/or Durie‐Salmon stage, high‐risk cytogenetics, melphalan dose, and disease status at and 1 year after transplant. AHCT utilization rate using the Surveillance, Epidemiology, and End Results database was used to estimate specific incidence among ≥75 years old by race and gender.Results: Of 360 patients, 63% were male, 84% were White, 56% had KPS P = .02). There was 3.37‐3.79% transplant utilization in White females compared to 1.88‐2.12% in African American females (P < .01).Conclusions: The use of AHCT was associated with excellent 2‐year outcomes in this selected MM population ≥75 years old. Transplant utilization for patients ≥75 years old remains low with significant racial and gender disparities.
Funding Information
  • Health Resources and Services Administration (HHSH250201700006C, HHSH250201700007C)
  • Office of Naval Research (N00014‐20‐1‐2705, N00014‐20‐1‐2832)

This publication has 21 references indexed in Scilit: